Positive data for atogepant in prophylaxis of migraine headaches presented at conference
In the Phase III placebo-controlled ADVANCE trial, use of atogepant among individuals experiencing 4-14 migraine days per month was associated with ≥50% reduction in monthly migraine frequency in 55.6%-60.8% (10-60mg doses) versus 29% placebo [no statistical significance stated].
Source:
Biospace Inc.